2020
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Klemen ND, Wang M, Rubinstein JC, Olino K, Clune J, Ariyan S, Cha C, Weiss SA, Kluger HM, Sznol M. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: e000341. PMID: 32209601, PMCID: PMC7103823, DOI: 10.1136/jitc-2019-000341.Peer-Reviewed Original ResearchConceptsCheckpoint inhibitorsOverall survivalMetastatic melanomaPrimary tumorLocal therapyCutaneous melanomaAnti-PD-1 antibodyAggressive multidisciplinary approachCutaneous primary tumorPrimary tumor histologyMedian overall survivalSingle institutional experienceRare melanoma subtypeMedian OSMetastatic diseaseProgressive diseaseAcral skinComplete responsePD-1PD-L1Uveal tractTumor histologyCombination therapyCTLA-4Longer survival
2016
Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival
Bordia R, Zhong H, Lee J, Weiss S, Han SW, Osman I, Jain R. Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival. Journal Of Neuro-Oncology 2016, 131: 341-348. PMID: 27822597, DOI: 10.1007/s11060-016-2305-8.Peer-Reviewed Original ResearchConceptsMelanoma brain metastasesSignificant prognostic factorsBRAF inhibitor treatmentPercent of lesionsBrain metastasesMedian survivalPrognostic factorsPatient survivalMultiple lesionsInhibitor treatmentT1-weighted hyperintensityBRAF mutation statusT1-weighted hyperintense signalsNumber of lesionsMethods PatientsRetrospective reviewInstitutional databaseLonger survivalHyperintense signalBrain MRIMelanoma metastasesSingle lesionEnhancement patternLarge lesionsLesion size